Summary
The share price has essentially doubled since last year's IPO.
The valuation gap with larger competitor Blueprint Medicines appears enticing, even after the latter's recent decline.
Initial data for DCC-2618 in GIST patients was encouraging and provides significant derisking.
Management commentary at a recent presentation, strengthening of leadership & the Board of Directors and institutional positioning all bode well.
As the company is well-capitalized and ESMO approaches, I suggest initiating a pilot position in the near term and buying the dips.
Looking for a portfolio of ideas like this one? Members of ROTY get exclusive access to our model portfolio. Get started today ยป
Shares of Deciphera Pharmaceuticals (DCPH) have essentially doubled from the IPO price point of $17 (took place in late September of last year). So far in 2018 the stock has risen by about 55%.
For what it's worth, Blueprint Medicines (BPMC), a front-runner in the same space, was a recommendation of mine which even after the pullback has done quite well.

